Dassault Systèmes has signed a definitive agreement to acquire ArisGlobal, an AI-native enterprise compliance platform serving the life sciences industry. ArisGlobal‘s platform supports regulatory, safety, quality and medical affairs functions across biopharma, biotech, medtech, contract research organisations and global health authorities.
The acquisition aims to combine ArisGlobal’s real-world patient insights with Dassault Systèmes‘ modelling and simulation expertise in research and development, clinical development and manufacturing, creating what the companies describe as a unified intelligence platform connecting molecule, patient and real-world outcomes. According to Dassault Systèmes, the transaction aligns with its industrial AI roadmap and remains subject to customary regulatory approvals and other closing conditions.
Image generated by: ChatGPT